Clinical pharmacokinetics of mycophenolate mofetil
The pharmacokinetics of the immunosuppressant mycophenolate mofetil have been investigated in healthy volunteers and mainly in recipients of renal allografts. Following oral administration, mycophenolate mofetil was rapidly and completely absorbed, and underwent extensive presystemic de-esterificati...
Saved in:
Published in | Clinical pharmacokinetics Vol. 34; no. 6; pp. 429 - 455 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Auckland
Adis international
01.06.1998
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The pharmacokinetics of the immunosuppressant mycophenolate mofetil have been investigated in healthy volunteers and mainly in recipients of renal allografts. Following oral administration, mycophenolate mofetil was rapidly and completely absorbed, and underwent extensive presystemic de-esterification. Systemic plasma clearance of intravenous mycophenolate mofetil was around 10 L/min in healthy individuals, and plasma mycophenolate mofetil concentrations fell below the quantitation limit (0.4 mg/L) within 10 minutes of the cessation of infusion. Similar plasma mycophenolate mofetil concentrations were seen after intravenous administration in patients with severe renal or hepatic impairment, implying that the de-esterification process had not been substantially affected. Mycophenolic acid, the active immunosuppressant species, is glucuronidated to a stable phenolic glucuronide (MPAG) which is not pharmacologically active. Over 90% of the administered dose is eventually excreted in the urine, mostly as MPAG. The magnitude of the MPAG renal clearance indicates that active tubular secretion of MPAG must occur. At clinically relevant concentrations, mycophenolic acid and MPAG are about 97% and 82% bound to albumin, respectively. MPAG at high (but clinically realisable) concentrations reduced the plasma binding of mycophenolic acid. The mean maximum plasma mycophenolic acid concentration (Cmax) after a mycophenolate mofetil 1 g dose in healthy individuals was around 25 mg/L, occurred at 0.8 hours postdose, decayed with a mean apparent half-life (t1/2) of around 16 hours, and generated a mean total area under the plasma concentration-time curve (AUC infinity) of around 64 mg.h/L. Intra- and interindividual coefficients of variation for the AUC infinity of the drug were estimated to be 25% and 10%, respectively. Intravenous and oral administration of mycophenolate mofetil showed statistically equivalent MPA AUC infinity values in healthy individuals. Compared with mycophenolic acid, MPAG showed a roughly similar Cmax about 1 hour after mycophenolic acid Cmax, with a similar t1/2 and an AUC infinity about 5-fold larger than that for mycophenolic acid. Secondary mycophenolic acid peaks represent a significant enterohepatic cycling process. Since MPAG was the sole material excreted in bile, entrohepatic cycling must involve colonic bacterial deconjugation of MPAG. An oral cholestyramine interaction study showed that the mean contribution of entrohepatic cycling to the AUC infinity of mycophenolic acid was around 40% with a range of 10 to 60%. The pharmacokinetics of patients with renal transplants (after 3 months or more) compared with those of healthy individuals were similar after oral mycophenolate mofetil. Immediately post-transplant, the mean Cmax and AUC infinity of mycophenolic acid were 30 to 50% of those in the 3-month post-transplant patients. These parameters rose slowly over the 3-month interval. Slow metabolic changes, rather than poor absorption, seem responsible for this nonstationarity, since intravenous and oral administration of mycophenolate mofetil in the immediate post-transplant period generated comparable MPA AUC infinity values. Renal impairment had no major effect on the pharmacokinetic of mycophenolic acid after single doses of mycophenolate mofetil, but there was a progressive decrease in MPAG clearance as glomerular filtration rate (GFR) declined. Compared to individuals with a normal GFR, patients with severe renal impairment (GFR 1.5 L/h/1.73m2) showed 3-to 6-fold higher MPAG AUC values. In rental transplant recipients during acute renal impairment in the early post-transplant period, the plasma MPA concentrations were comparable to those in patients without renal failure, whereas plasma MPAG concentrations were 2- to 3-fold higher. Haemodialysis had no major effect on plasma mycophenolic acid or MPAG. Dosage adjustments appear to not be necessary either in renal impairment or during dialysis. (ABSTRACT TRUN |
---|---|
AbstractList | The pharmacokinetics of the immunosuppressant mycophenolate mofetil have been investigated in healthy volunteers and mainly in recipients of renal allografts. Following oral administration, mycophenolate mofetil was rapidly and completely absorbed, and underwent extensive presystemic de-esterification. Systemic plasma clearance of intravenous mycophenolate mofetil was around 10 L/min in healthy individuals, and plasma mycophenolate mofetil concentrations fell below the quantitation limit (0.4 mg/L) within 10 minutes of the cessation of infusion. Similar plasma mycophenolate mofetil concentrations were seen after intravenous administration in patients with severe renal or hepatic impairment, implying that the de-esterification process had not been substantially affected. Mycophenolic acid, the active immunosuppressant species, is glucuronidated to a stable phenolic glucuronide (MPAG) which is not pharmacologically active. Over 90% of the administered dose is eventually excreted in the urine, mostly as MPAG. The magnitude of the MPAG renal clearance indicates that active tubular secretion of MPAG must occur. At clinically relevant concentrations, mycophenolic acid and MPAG are about 97% and 82% bound to albumin, respectively. MPAG at high (but clinically realisable) concentrations reduced the plasma binding of mycophenolic acid. The mean maximum plasma mycophenolic acid concentration (Cmax) after a mycophenolate mofetil 1 g dose in healthy individuals was around 25 mg/L, occurred at 0.8 hours postdose, decayed with a mean apparent half-life (t1/2) of around 16 hours, and generated a mean total area under the plasma concentration-time curve (AUC infinity) of around 64 mg.h/L. Intra- and interindividual coefficients of variation for the AUC infinity of the drug were estimated to be 25% and 10%, respectively. Intravenous and oral administration of mycophenolate mofetil showed statistically equivalent MPA AUC infinity values in healthy individuals. Compared with mycophenolic acid, MPAG showed a roughly similar Cmax about 1 hour after mycophenolic acid Cmax, with a similar t1/2 and an AUC infinity about 5-fold larger than that for mycophenolic acid. Secondary mycophenolic acid peaks represent a significant enterohepatic cycling process. Since MPAG was the sole material excreted in bile, entrohepatic cycling must involve colonic bacterial deconjugation of MPAG. An oral cholestyramine interaction study showed that the mean contribution of entrohepatic cycling to the AUC infinity of mycophenolic acid was around 40% with a range of 10 to 60%. The pharmacokinetics of patients with renal transplants (after 3 months or more) compared with those of healthy individuals were similar after oral mycophenolate mofetil. Immediately post-transplant, the mean Cmax and AUC infinity of mycophenolic acid were 30 to 50% of those in the 3-month post-transplant patients. These parameters rose slowly over the 3-month interval. Slow metabolic changes, rather than poor absorption, seem responsible for this nonstationarity, since intravenous and oral administration of mycophenolate mofetil in the immediate post-transplant period generated comparable MPA AUC infinity values. Renal impairment had no major effect on the pharmacokinetic of mycophenolic acid after single doses of mycophenolate mofetil, but there was a progressive decrease in MPAG clearance as glomerular filtration rate (GFR) declined. Compared to individuals with a normal GFR, patients with severe renal impairment (GFR 1.5 L/h/1.73m2) showed 3-to 6-fold higher MPAG AUC values. In rental transplant recipients during acute renal impairment in the early post-transplant period, the plasma MPA concentrations were comparable to those in patients without renal failure, whereas plasma MPAG concentrations were 2- to 3-fold higher. Haemodialysis had no major effect on plasma mycophenolic acid or MPAG. Dosage adjustments appear to not be necessary either in renal impairment or during dialysis. (ABSTRACT TRUN |
Author | KAMM, B. R BULLINGHAM, R. E. S NICHOLLS, A. J |
Author_xml | – sequence: 1 givenname: R. E. S surname: BULLINGHAM fullname: BULLINGHAM, R. E. S organization: CS Associates, Palo Alto, United States – sequence: 2 givenname: A. J surname: NICHOLLS fullname: NICHOLLS, A. J organization: CS Associates, Palo Alto, United States – sequence: 3 givenname: B. R surname: KAMM fullname: KAMM, B. R organization: CS Associates, Palo Alto, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2441708$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9646007$$D View this record in MEDLINE/PubMed |
BookMark | eNo9UMtKw0AUHaRS0-onCFm4jd55zywl-IKCG12HyTxoNMmETF30753a2rs5cB4XzlmhxRhHj1CJ4Z5gwR8gHwWlKqy1ogwEVAeKXKACY6kzTcQCFUAxqbgW9AqtUvrKDkUAlmipBRMAskCk7ruxs6Yvp62ZB2Pjdzf6XWdTGUM57G2ctn6Mvdn5coghK_01ugymT_7mhGv0-fz0Ub9Wm_eXt_pxU1kGfFcR2lrCqPQ2WE6ZoVIFjLXDlGgOQhvwFAJTTjnHPMbMOJCSt9xY4hQ4ukbq-NfOMaXZh2aau8HM-wZDc1ih-V-hOa_wR5EcvT1Gp5928O4cPNXO-t1JNyl3D7MZbZfONsIYlqDoL-s6ZZY |
CODEN | CPKNDH |
CitedBy_id | crossref_primary_10_1016_j_cca_2006_05_019 crossref_primary_10_3390_biomedicines11092562 crossref_primary_10_1111_j_1399_0012_2008_00932_x crossref_primary_10_4049_jimmunol_1003319 crossref_primary_10_1007_s40268_020_00319_y crossref_primary_10_1016_j_jchromb_2006_07_062 crossref_primary_10_1097_FTD_0b013e318068619d crossref_primary_10_1097_FTD_0b013e3181a23f1a crossref_primary_10_2165_00003088_200241110_00003 crossref_primary_10_1248_yakushi_126_1357 crossref_primary_10_1038_bmt_2008_85 crossref_primary_10_1093_ndt_gfq819 crossref_primary_10_1097_FTD_0b013e31815f5416 crossref_primary_10_1016_j_clinthera_2008_04_014 crossref_primary_10_1097_00007691_200608000_00004 crossref_primary_10_2217_14622416_9_7_869 crossref_primary_10_1016_j_transproceed_2006_12_027 crossref_primary_10_3109_07420528_2015_1082481 crossref_primary_10_1016_j_ucl_2021_12_010 crossref_primary_10_1007_s00204_009_0476_1 crossref_primary_10_1124_dmd_110_034249 crossref_primary_10_1007_s00228_008_0501_y crossref_primary_10_1016_j_transproceed_2016_10_018 crossref_primary_10_1034_j_1399_0012_2001_150306_x crossref_primary_10_1016_j_jaad_2008_08_049 crossref_primary_10_1021_mp050018m crossref_primary_10_1080_07420528_2016_1211139 crossref_primary_10_1124_dmd_106_012013 crossref_primary_10_1097_01_tp_0000276936_14041_6c crossref_primary_10_1016_j_survophthal_2011_05_003 crossref_primary_10_1097_FTD_0b013e318074d979 crossref_primary_10_1111_j_1432_2277_2010_01196_x crossref_primary_10_1097_FTD_0b013e3181aa36cd crossref_primary_10_1080_15287394_2017_1286922 crossref_primary_10_1007_s00204_012_0922_3 crossref_primary_10_1097_FTD_0b013e3181f01397 crossref_primary_10_1007_s13318_017_0420_3 crossref_primary_10_1111_j_1365_2710_2009_01053_x crossref_primary_10_1111_j_1600_6143_2009_02733_x crossref_primary_10_1124_dmd_115_068643 crossref_primary_10_1080_17425255_2021_2027906 crossref_primary_10_1002_jcla_21565 crossref_primary_10_1016_S0003_2670_03_00410_0 crossref_primary_10_1002_prp2_1103 crossref_primary_10_1097_01_ftd_0000167885_17280_6f crossref_primary_10_1016_S0162_3109_00_00193_4 crossref_primary_10_1021_bc400369t crossref_primary_10_1111_petr_14077 crossref_primary_10_1016_j_kint_2021_06_036 crossref_primary_10_1053_jhep_2002_31607 crossref_primary_10_1002_cpdd_1141 crossref_primary_10_1111_j_1399_0012_2005_00387_x crossref_primary_10_1016_j_jchromb_2004_02_020 crossref_primary_10_1007_s12016_023_08963_3 crossref_primary_10_1038_s41397_019_0086_0 crossref_primary_10_1111_cei_13371 crossref_primary_10_1111_j_1600_6143_2007_01983_x crossref_primary_10_1007_s40262_021_01037_7 crossref_primary_10_1248_bpb_29_2099 crossref_primary_10_1111_j_1399_0012_2006_00569_x crossref_primary_10_1016_j_clinpr_2022_100211 crossref_primary_10_1080_00498250902807338 crossref_primary_10_4285_jkstn_2018_32_4_75 crossref_primary_10_1177_0091270011413895 crossref_primary_10_1016_S0003_2670_03_00359_3 crossref_primary_10_1016_j_plabm_2016_12_002 crossref_primary_10_1081_CLT_200035101 crossref_primary_10_1016_j_clinbiochem_2005_05_008 crossref_primary_10_1007_s00467_023_05927_9 crossref_primary_10_1016_j_bpg_2021_101756 crossref_primary_10_1080_17425255_2020_1803277 crossref_primary_10_1097_FTD_0b013e3181aa776e crossref_primary_10_1111_j_1399_0012_2004_00203_x crossref_primary_10_1016_j_jchromb_2003_10_074 crossref_primary_10_1097_FTD_0000000000000081 crossref_primary_10_1021_mp400513k crossref_primary_10_1016_j_clinthera_2010_01_013 crossref_primary_10_1097_00007691_200108000_00001 crossref_primary_10_1016_S1699_258X_06_73055_8 crossref_primary_10_1080_00498254_2016_1214885 crossref_primary_10_3389_fphar_2020_00340 crossref_primary_10_1111_jvp_12338 crossref_primary_10_1007_s00280_018_3550_7 crossref_primary_10_1111_jvp_12420 crossref_primary_10_1002_pauz_200500133 crossref_primary_10_1007_s40262_017_0603_8 crossref_primary_10_1097_TP_0000000000004646 crossref_primary_10_1097_FTD_0b013e3182a37a1e crossref_primary_10_1007_s11904_014_0212_1 crossref_primary_10_1016_j_transproceed_2005_03_090 crossref_primary_10_1016_j_clinthera_2004_11_004 crossref_primary_10_1177_0091270004271555 crossref_primary_10_1177_0091270009332813 crossref_primary_10_1097_FTD_0b013e3181efd715 crossref_primary_10_1097_00007890_200105270_00013 crossref_primary_10_1111_aor_13623 crossref_primary_10_1016_j_xphs_2017_05_010 crossref_primary_10_1007_s13318_016_0378_6 crossref_primary_10_1002_ajmg_a_32420 crossref_primary_10_1002_jcla_21599 crossref_primary_10_1016_j_ejps_2020_105370 crossref_primary_10_1016_j_transproceed_2005_09_202 crossref_primary_10_1093_clinchem_47_8_1485 crossref_primary_10_1177_2055116920963995 crossref_primary_10_46310_tjim_632066 crossref_primary_10_1161_01_CIR_0000151805_86933_35 crossref_primary_10_1111_ctr_13893 crossref_primary_10_1111_j_1365_2125_2011_04140_x crossref_primary_10_1097_TXD_0000000000000754 crossref_primary_10_1517_14656566_9_6_879 crossref_primary_10_1016_j_bbmt_2014_03_032 crossref_primary_10_1007_s10928_009_9136_6 crossref_primary_10_1124_jpet_106_104810 crossref_primary_10_1016_j_jchromb_2007_09_036 crossref_primary_10_1111_tri_12382 crossref_primary_10_1182_blood_2009_02_202937 crossref_primary_10_2165_11536640_000000000_00000 crossref_primary_10_1038_sj_bjp_0702399 crossref_primary_10_1111_j_1365_2125_2005_02398_x crossref_primary_10_1002_bmc_5011 crossref_primary_10_1080_00498254_2017_1329567 crossref_primary_10_1186_s40697_015_0059_4 crossref_primary_10_1002_jcph_348 crossref_primary_10_1097_FTD_0000000000000052 crossref_primary_10_1517_17425255_3_2_251 crossref_primary_10_1097_FTD_0000000000000170 crossref_primary_10_1002_lt_21600 crossref_primary_10_1097_FTD_0b013e31818b8244 crossref_primary_10_1111_j_1399_3046_2005_00386_x crossref_primary_10_1016_S0955_470X_03_00022_3 crossref_primary_10_1097_01_ftd_0000211821_73231_8a crossref_primary_10_1097_FTD_0b013e31820271c3 crossref_primary_10_1177_0897190003259383 crossref_primary_10_1016_j_trre_2011_01_001 crossref_primary_10_3390_nu14204220 crossref_primary_10_1038_ki_2013_517 crossref_primary_10_2165_11319320_000000000_00000 crossref_primary_10_1097_FTD_0000000000000165 crossref_primary_10_1080_09273940590951034 crossref_primary_10_1186_s12929_020_00704_4 crossref_primary_10_1345_aph_1H149 crossref_primary_10_1016_j_jchromb_2007_08_023 crossref_primary_10_1097_00007890_200006150_00018 crossref_primary_10_1111_j_1365_2710_2011_01269_x crossref_primary_10_1111_j_1476_4431_2000_tb00009_x crossref_primary_10_1517_14656566_4_12_2325 crossref_primary_10_1007_s00228_007_0380_7 crossref_primary_10_2165_00003088_200241100_00005 crossref_primary_10_1016_j_det_2011_06_012 crossref_primary_10_1515_JLM_2006_047 crossref_primary_10_1002_hep_21464 crossref_primary_10_3904_kjm_2019_94_5_455 crossref_primary_10_1111_j_1365_2125_2005_02509_x crossref_primary_10_1016_j_dmpk_2014_09_007 crossref_primary_10_1016_j_healun_2009_03_006 crossref_primary_10_1038_s41598_018_37852_5 crossref_primary_10_1159_000351180 crossref_primary_10_3109_00365513_2012_745947 crossref_primary_10_1515_CCLM_2011_194 crossref_primary_10_2146_ajhp110287 crossref_primary_10_1016_j_bbmt_2006_07_009 crossref_primary_10_1016_j_xphs_2020_10_028 crossref_primary_10_1111_bcp_12678 crossref_primary_10_1016_j_ijpharm_2014_06_056 crossref_primary_10_1093_ndt_14_11_2710 crossref_primary_10_1097_FPC_0b013e32801430f8 crossref_primary_10_1038_sj_bmt_1705958 crossref_primary_10_1097_00007691_199906000_00013 crossref_primary_10_1046_j_1365_2125_2003_01863_x crossref_primary_10_1111_j_1365_2125_2012_04213_x crossref_primary_10_1080_00498254_2016_1235742 crossref_primary_10_1097_TP_0b013e31820813c0 crossref_primary_10_1097_00007691_200408000_00002 crossref_primary_10_1093_clinchem_46_3_365 crossref_primary_10_1155_2013_897434 crossref_primary_10_1111_j_1440_1797_2007_00862_x crossref_primary_10_2165_00003088_200443040_00004 crossref_primary_10_1016_j_trre_2018_11_001 crossref_primary_10_1016_j_cger_2021_01_007 crossref_primary_10_1124_dmd_106_010140 crossref_primary_10_1097_01_tp_0000235533_29300_e7 crossref_primary_10_1097_FTD_0b013e3181fc8fbb crossref_primary_10_1097_TXD_0000000000001058 crossref_primary_10_1177_0884533613490740 crossref_primary_10_1586_egh_12_38 crossref_primary_10_1007_s00467_008_0877_z crossref_primary_10_1034_j_1399_0012_2002_01122_x crossref_primary_10_2165_00003088_200241050_00001 crossref_primary_10_2165_0003495_200868170_00007 crossref_primary_10_1097_FPC_0000000000000010 crossref_primary_10_1111_tid_12275 crossref_primary_10_1365_s10337_009_1223_8 crossref_primary_10_1016_j_suc_2006_06_013 crossref_primary_10_1097_TP_0b013e3181b0e608 crossref_primary_10_1007_s40261_018_0652_2 crossref_primary_10_1592_phco_29_1_7 crossref_primary_10_1016_j_biochi_2006_09_016 crossref_primary_10_1111_j_1365_2710_2008_00906_x crossref_primary_10_1007_s00431_021_04294_7 crossref_primary_10_1124_dmd_110_037457 crossref_primary_10_1152_ajprenal_1999_277_2_F312 crossref_primary_10_1002_bmc_1088 crossref_primary_10_1186_s40780_017_0086_7 crossref_primary_10_1097_FTD_0000000000000360 crossref_primary_10_1038_sj_bmt_1703633 crossref_primary_10_1038_s41584_020_0374_8 crossref_primary_10_1111_ced_12650 crossref_primary_10_1177_0091270008329558 crossref_primary_10_1080_17425255_2021_1843633 crossref_primary_10_2165_11316480_000000000_00000 crossref_primary_10_1016_j_transproceed_2010_03_004 crossref_primary_10_1038_bmt_2008_428 crossref_primary_10_1016_j_bbmt_2009_10_007 crossref_primary_10_1007_s40620_021_01183_y crossref_primary_10_1046_j_1523_1755_2002_00531_x crossref_primary_10_1111_jvp_12731 crossref_primary_10_1517_17425255_2015_1033397 crossref_primary_10_1097_FTD_0b013e3181e6b348 crossref_primary_10_4155_ipk_2017_0014 crossref_primary_10_1517_14656566_5_6_1333 crossref_primary_10_1186_1471_2261_5_9 crossref_primary_10_1097_FTD_0b013e3182708f84 crossref_primary_10_1111_bcp_13850 crossref_primary_10_1097_01_ftd_0000177664_96726_56 crossref_primary_10_1111_j_1365_2125_2005_02541_x crossref_primary_10_1097_01_TP_0000137262_06252_05 crossref_primary_10_1016_j_transproceed_2023_12_019 crossref_primary_10_1007_s00467_015_3303_3 crossref_primary_10_3389_fphar_2021_802539 crossref_primary_10_1016_j_atherosclerosis_2010_01_018 crossref_primary_10_1016_j_bbmt_2009_11_010 crossref_primary_10_2165_0003088_200847120_00007 crossref_primary_10_1345_aph_1L699 crossref_primary_10_3390_jcm11061597 crossref_primary_10_2478_v10136_012_0024_9 crossref_primary_10_3109_00498254_2015_1103386 crossref_primary_10_1016_j_cell_2020_05_001 crossref_primary_10_7759_cureus_17417 crossref_primary_10_1097_FTD_0b013e318191897d crossref_primary_10_1046_j_0306_5251_2001_01487_x crossref_primary_10_1097_00007691_200310000_00011 crossref_primary_10_1517_17425255_2011_570260 crossref_primary_10_1016_j_ejps_2021_105812 crossref_primary_10_1016_j_jpba_2009_05_030 crossref_primary_10_1002_bmc_3682 crossref_primary_10_1186_1475_2875_13_476 crossref_primary_10_1016_j_jchromb_2007_02_038 crossref_primary_10_1097_01_tp_0000186380_61251_fc crossref_primary_10_1081_DDC_120015361 crossref_primary_10_1016_S0041_1345_98_01936_8 crossref_primary_10_1093_clinchem_45_3_419 crossref_primary_10_1139_cjpp_2019_0383 crossref_primary_10_1136_bmjopen_2013_003511 crossref_primary_10_1097_TP_0000000000004926 crossref_primary_10_1038_s41409_024_02331_1 crossref_primary_10_1002_bmc_4681 crossref_primary_10_1016_S0378_4347_00_00273_5 crossref_primary_10_2217_pgs_2018_0114 crossref_primary_10_1124_dmd_113_055558 crossref_primary_10_1177_0091270010382909 crossref_primary_10_3390_pharmaceutics12040312 crossref_primary_10_1093_ndt_gfn360 crossref_primary_10_1016_j_cair_2005_12_001 crossref_primary_10_1016_j_pop_2011_05_006 crossref_primary_10_1016_S0041_1345_00_01390_7 crossref_primary_10_1111_j_1399_0012_2009_01166_x crossref_primary_10_2133_dmpk_DMPK_12_RV_042 crossref_primary_10_1016_j_ijpharm_2014_12_003 crossref_primary_10_1097_01_ftd_0000162231_90811_38 crossref_primary_10_1097_FTD_0b013e3181e6b54d crossref_primary_10_1097_00007691_200206000_00011 crossref_primary_10_4155_bio_10_99 crossref_primary_10_2217_pgs_10_132 crossref_primary_10_1097_00075200_200009000_00016 crossref_primary_10_3390_ijms231710070 crossref_primary_10_1124_dmd_105_004663 crossref_primary_10_1097_BOR_0b013e32832a0698 crossref_primary_10_1002_cptx_42 crossref_primary_10_1097_FTD_0b013e31820c0a96 crossref_primary_10_1097_00007691_200104000_00005 crossref_primary_10_1039_D2LC00276K crossref_primary_10_1128_AAC_01138_08 crossref_primary_10_3389_fphar_2021_742444 crossref_primary_10_1097_00007691_200412000_00005 crossref_primary_10_1016_j_chom_2016_07_004 crossref_primary_10_1097_00007691_200206000_00019 crossref_primary_10_1097_FTD_0b013e3181b8679a crossref_primary_10_1097_00007691_200412000_00004 crossref_primary_10_1124_dmd_117_079236 crossref_primary_10_2217_pgs_2021_0102 crossref_primary_10_1053_j_ackd_2012_09_002 crossref_primary_10_1097_00007691_200002000_00004 crossref_primary_10_1097_00007691_200002000_00003 crossref_primary_10_1016_S0041_1345_02_03489_9 crossref_primary_10_1034_j_1399_0012_2001_150607_x crossref_primary_10_1111_j_1365_2125_2006_02813_x crossref_primary_10_1080_00498250802488585 crossref_primary_10_1097_FTD_0000000000000871 crossref_primary_10_1517_14656566_7_4_361 crossref_primary_10_1177_0091270004267808 crossref_primary_10_1002_lt_21146 crossref_primary_10_1111_j_1365_2125_2010_03615_x crossref_primary_10_1007_s00228_022_03295_1 crossref_primary_10_1055_a_1176_6466 crossref_primary_10_1034_j_1399_0012_2000_140301_x crossref_primary_10_1002_bmc_4989 crossref_primary_10_2165_00003088_200443120_00004 crossref_primary_10_1007_s00228_012_1409_0 crossref_primary_10_1177_0091270005278599 crossref_primary_10_1517_17425255_3_1_93 crossref_primary_10_2217_pme_2021_0092 crossref_primary_10_1007_s40495_017_0096_z crossref_primary_10_1016_j_iac_2012_04_010 crossref_primary_10_1046_j_1600_6135_2003_00243_x crossref_primary_10_1111_jvim_16797 crossref_primary_10_1111_jvim_15585 crossref_primary_10_3389_fphar_2021_748609 crossref_primary_10_1111_j_1432_2277_2005_00228_x crossref_primary_10_1177_17534666221117002 crossref_primary_10_1038_clpt_2009_3 crossref_primary_10_1111_imj_13404 crossref_primary_10_1586_1744666X_2_4_495 crossref_primary_10_1097_IAE_0b013e31828b91e6 crossref_primary_10_1038_clpt_2009_129 crossref_primary_10_1016_j_cca_2011_12_003 crossref_primary_10_1097_00007691_200302000_00001 crossref_primary_10_1007_s00228_015_1854_7 crossref_primary_10_1021_mp060011k crossref_primary_10_1002_pmic_200300836 crossref_primary_10_1373_clinchem_2004_047357 crossref_primary_10_1080_00498254_2020_1813352 crossref_primary_10_2165_00003088_200746010_00002 crossref_primary_10_2460_ajvr_79_10_1093 crossref_primary_10_1093_ndt_gfaa111 crossref_primary_10_1097_FTD_0000000000000533 crossref_primary_10_1097_PCC_0000000000000626 crossref_primary_10_1111_petr_12695 crossref_primary_10_1097_FTD_0b013e3181ae44b9 crossref_primary_10_1111_j_1365_2125_2006_02509_x crossref_primary_10_1016_j_cca_2007_11_033 crossref_primary_10_1016_j_transproceed_2015_11_014 crossref_primary_10_1097_FTD_0b013e3181c01d07 crossref_primary_10_1177_0091270011422814 crossref_primary_10_1097_FTD_0b013e3181633667 crossref_primary_10_1177_0091270007301624 crossref_primary_10_1097_MBC_0000000000000886 crossref_primary_10_1053_jlts_2003_50022 crossref_primary_10_1016_j_cca_2006_02_017 crossref_primary_10_1016_j_transproceed_2004_12_282 crossref_primary_10_1177_0961203320931567 crossref_primary_10_1016_j_toxlet_2014_10_009 crossref_primary_10_1002_elps_200700952 crossref_primary_10_1038_cmi_2016_39 crossref_primary_10_1592_phco_27_9_1272 crossref_primary_10_1002_bmc_3423 crossref_primary_10_1016_j_transproceed_2014_01_012 crossref_primary_10_1016_j_clinbiochem_2012_11_025 crossref_primary_10_1016_S0270_9295_03_00066_4 crossref_primary_10_1038_s41582_020_0313_y crossref_primary_10_1097_01_ftd_0000163949_40686_0f crossref_primary_10_1016_S0041_1345_02_03051_8 crossref_primary_10_1016_S0923_2532_01_80080_6 crossref_primary_10_1080_00498254_2023_2287168 crossref_primary_10_2165_00003088_200544100_00006 crossref_primary_10_1097_01_ftd_0000211826_65607_05 crossref_primary_10_1097_TP_0b013e318223d7f3 crossref_primary_10_1016_j_intimp_2008_01_023 crossref_primary_10_1097_FTD_0b013e3181f6502d crossref_primary_10_1016_S0166_3542_00_00145_5 crossref_primary_10_1038_aps_2017_115 crossref_primary_10_1365_s10337_005_0635_3 crossref_primary_10_1002_mas_20235 crossref_primary_10_2217_pgs_15_7 crossref_primary_10_1002_jcph_1423 crossref_primary_10_1111_j_1365_2125_2010_03734_x crossref_primary_10_1016_j_transproceed_2004_12_186 crossref_primary_10_1016_j_jpba_2016_01_059 crossref_primary_10_1097_00007691_199910000_00002 crossref_primary_10_1007_s40262_015_0340_9 crossref_primary_10_1124_dmd_106_010553 crossref_primary_10_1016_j_transproceed_2018_02_068 crossref_primary_10_1093_ndt_17_2_318 crossref_primary_10_1038_sj_clpt_6100300 crossref_primary_10_3389_fphar_2021_652333 crossref_primary_10_1097_01_TP_0000083895_64198_10 crossref_primary_10_1097_FPC_0000000000000045 crossref_primary_10_1111_j_1600_6143_2005_01151_x crossref_primary_10_2215_CJN_07111009 crossref_primary_10_3390_jpm14040440 crossref_primary_10_1097_FTD_0b013e318180c709 crossref_primary_10_2165_00003088_200746050_00002 crossref_primary_10_1111_1756_185X_12281 crossref_primary_10_1111_j_1432_2277_2004_tb00394_x crossref_primary_10_1097_FTD_0b013e31829dcb66 crossref_primary_10_1111_ddg_15270 crossref_primary_10_3109_03602532_2016_1157600 crossref_primary_10_1002_art_27495 crossref_primary_10_1185_030079906X148481 crossref_primary_10_3390_pharmaceutics15061734 crossref_primary_10_1016_j_cccn_2005_02_023 crossref_primary_10_1016_j_jpba_2004_07_034 crossref_primary_10_1097_00007691_200204000_00013 crossref_primary_10_3109_00498254_2012_761742 crossref_primary_10_3390_biomedicines10081798 crossref_primary_10_1097_00007691_200306000_00025 crossref_primary_10_1016_j_lfs_2024_122792 crossref_primary_10_1517_17425255_1_3_505 crossref_primary_10_1016_j_bcp_2007_03_024 crossref_primary_10_1016_j_transproceed_2006_10_189 crossref_primary_10_1097_01_ftd_0000189898_23931_3f crossref_primary_10_1097_00007691_200010000_00008 crossref_primary_10_23876_j_krcp_20_059 crossref_primary_10_2165_11317240_000000000_00000 crossref_primary_10_1046_j_1365_2710_2003_00536_x crossref_primary_10_1016_S0041_1345_00_02322_8 crossref_primary_10_1177_0091270003256151 crossref_primary_10_1002_jcph_1565 crossref_primary_10_1097_TP_0b013e318225dbd0 crossref_primary_10_1021_es051886f crossref_primary_10_12737_2409_3750_2023_8_4_13_19 crossref_primary_10_1016_j_bmc_2014_12_051 crossref_primary_10_1111_j_1365_2125_2010_03625_x crossref_primary_10_1046_j_1523_1755_2002_00325_x crossref_primary_10_1002_lt_22364 crossref_primary_10_1002_lt_21274 crossref_primary_10_1016_j_pharep_2016_06_001 crossref_primary_10_1016_S0041_1345_01_02830_5 crossref_primary_10_1016_j_clinms_2017_07_001 crossref_primary_10_1097_FTD_0b013e31805d8816 crossref_primary_10_1002_cbdv_200790169 crossref_primary_10_1016_j_clim_2012_12_010 crossref_primary_10_1365_s10337_010_1715_6 crossref_primary_10_1007_s00228_006_0215_y crossref_primary_10_1111_j_1432_2277_2002_tb00164_x crossref_primary_10_1016_j_clinbiochem_2008_10_004 crossref_primary_10_1097_01_rhu_0000135555_83088_a2 crossref_primary_10_1016_S0041_1345_00_02424_6 crossref_primary_10_1007_s00228_006_0248_2 crossref_primary_10_1097_00000441_200204000_00005 crossref_primary_10_1345_aph_1D099 crossref_primary_10_1002_lt_20210 crossref_primary_10_1016_S0009_9120_00_00184_3 crossref_primary_10_1051_ata_2011125 crossref_primary_10_1097_01_tp_0000187133_53916_8f crossref_primary_10_1124_dmd_104_001651 crossref_primary_10_1515_JLM_2009_017 crossref_primary_10_1002_jssc_201500779 crossref_primary_10_1086_340867 crossref_primary_10_1177_0091270006295064 crossref_primary_10_1007_s00467_019_04428_y crossref_primary_10_1097_01_tp_0000436100_65983_10 crossref_primary_10_1080_00032710701583466 crossref_primary_10_1111_j_1463_1318_2004_00695_x crossref_primary_10_1016_j_chroma_2012_04_008 crossref_primary_10_1016_j_jpba_2007_12_028 crossref_primary_10_1211_0022357991776831 crossref_primary_10_1373_clinchem_2008_113936 crossref_primary_10_1097_01_tp_0000232697_38021_9a crossref_primary_10_1016_j_bbrc_2017_10_037 crossref_primary_10_1124_dmd_32_8_775 crossref_primary_10_1080_17425255_2021_1943356 crossref_primary_10_1177_0961203307079566 crossref_primary_10_1016_j_yexcr_2014_01_021 crossref_primary_10_1002_jcph_1064 crossref_primary_10_1002_lt_21895 crossref_primary_10_1111_j_1365_2125_2012_04372_x crossref_primary_10_1016_j_pharmthera_2013_09_002 crossref_primary_10_1111_ctr_14260 crossref_primary_10_1002_lt_21657 crossref_primary_10_1111_j_1365_2710_2009_01034_x crossref_primary_10_15369_sujms_35_178 crossref_primary_10_2133_dmpk_21_406 crossref_primary_10_2165_00003088_200948050_00005 crossref_primary_10_1097_FTD_0b013e31803d37b6 crossref_primary_10_1515_CCLM_2008_243 crossref_primary_10_1007_s11096_019_00848_w crossref_primary_10_1021_cr990097b crossref_primary_10_1007_s12185_016_2145_5 crossref_primary_10_1111_j_1432_2277_2004_00042_x crossref_primary_10_1177_0091270007313326 crossref_primary_10_1517_14740338_2014_903032 crossref_primary_10_1016_j_pharmthera_2020_107627 crossref_primary_10_1111_j_1600_6143_2005_01107_x crossref_primary_10_1016_j_jpha_2013_06_001 crossref_primary_10_1046_j_1600_6143_2005_00779_x crossref_primary_10_1002_bmc_3958 crossref_primary_10_1097_01_ftd_0000159784_25872_f6 crossref_primary_10_1016_j_mgene_2016_12_003 crossref_primary_10_1016_j_trim_2013_05_005 crossref_primary_10_1016_j_jpba_2003_12_011 crossref_primary_10_1016_j_clinthera_2006_06_015 crossref_primary_10_1097_TP_0b013e31820a6a79 crossref_primary_10_1111_j_1365_2710_2010_01168_x crossref_primary_10_1111_ddg_15270_g crossref_primary_10_1002_jcph_2176 crossref_primary_10_1097_FPC_0b013e32833d8cf5 crossref_primary_10_1016_j_bbmt_2011_11_029 crossref_primary_10_1097_FTD_0b013e318228195f crossref_primary_10_1038_ki_2010_84 crossref_primary_10_1097_01_TP_0000153301_27572_B2 crossref_primary_10_3389_fcvm_2024_1346475 crossref_primary_10_1248_bpb_34_755 crossref_primary_10_1016_j_jpba_2020_113337 crossref_primary_10_1179_acb_2007_034 crossref_primary_10_1517_17425255_2011_542149 crossref_primary_10_1124_dmd_104_001982 crossref_primary_10_1002_cpt_3288 crossref_primary_10_1002_bmc_3942 crossref_primary_10_1016_j_cld_2016_08_001 crossref_primary_10_1097_00007691_200202000_00011 crossref_primary_10_1016_j_transproceed_2009_08_078 crossref_primary_10_1097_00007691_200202000_00012 crossref_primary_10_1016_j_transproceed_2009_08_077 crossref_primary_10_1111_vde_13109 crossref_primary_10_1007_s12185_008_0093_4 crossref_primary_10_1038_aps_2015_7 crossref_primary_10_1016_j_healun_2007_12_009 crossref_primary_10_1016_j_fct_2023_114352 crossref_primary_10_1016_j_clinbiochem_2007_03_006 crossref_primary_10_1177_0091270009335003 crossref_primary_10_1053_j_ajkd_2004_03_021 crossref_primary_10_1034_j_1600_6143_2002_20806_x crossref_primary_10_1097_TP_0b013e3181744199 crossref_primary_10_2217_imt_11_148 crossref_primary_10_1097_FTD_0b013e3181838063 crossref_primary_10_1248_yakushi_130_1695 crossref_primary_10_1002_lt_21101 crossref_primary_10_1097_FTD_0b013e3181a8f0ae crossref_primary_10_2147_PGPM_S295964 crossref_primary_10_1373_clinchem_2005_065276 crossref_primary_10_1186_s40780_022_00271_w crossref_primary_10_1016_j_transproceed_2004_12_217 crossref_primary_10_1016_S0041_1345_99_00989_6 crossref_primary_10_1016_j_clinbiochem_2008_11_013 crossref_primary_10_1034_j_1399_3046_2001_005002112_x crossref_primary_10_2217_pgs_10_9 crossref_primary_10_1111_j_1600_6143_2005_00748_x crossref_primary_10_1111_j_1399_0012_2010_01226_x crossref_primary_10_1016_S0009_9120_00_00053_9 crossref_primary_10_1093_ndt_gfz095 crossref_primary_10_1111_jphp_12983 crossref_primary_10_1097_00007691_200006000_00009 crossref_primary_10_1093_ndt_gfr130 crossref_primary_10_1097_FTD_0b013e31816babef crossref_primary_10_1007_s10157_016_1267_7 crossref_primary_10_1038_clpt_2009_205 crossref_primary_10_1097_TP_0b013e31822dc34f crossref_primary_10_1002_lt_20124 crossref_primary_10_1016_j_ejps_2005_05_010 crossref_primary_10_1080_17474124_2020_1797483 crossref_primary_10_1097_TXD_0000000000001448 crossref_primary_10_1016_S0378_4347_01_00354_1 crossref_primary_10_1097_FTD_0b013e3182197e38 crossref_primary_10_2165_11312600_000000000_00000 crossref_primary_10_1016_j_transproceed_2021_07_003 crossref_primary_10_2460_ajvr_82_6_502 crossref_primary_10_1111_j_1432_2277_2000_tb02045_x crossref_primary_10_1111_j_1365_2125_2006_02841_x crossref_primary_10_1177_0963689720912925 crossref_primary_10_2515_therapie_2015033 crossref_primary_10_1038_sj_bjp_0703898 crossref_primary_10_1111_j_1365_2125_2008_03109_x crossref_primary_10_1016_j_trre_2010_12_003 crossref_primary_10_1159_000536468 crossref_primary_10_1177_0897190008315907 crossref_primary_10_2215_CJN_06050809 crossref_primary_10_1016_j_trre_2010_12_001 crossref_primary_10_1097_00007691_200304000_00003 crossref_primary_10_1097_FTD_0b013e318192693e crossref_primary_10_1097_FTD_0b013e3180686146 crossref_primary_10_1007_s00228_009_0721_9 crossref_primary_10_2165_00003088_200544080_00005 crossref_primary_10_2165_11594050_000000000_00000 crossref_primary_10_1034_j_1600_6143_2003_00079_x crossref_primary_10_1016_j_bmcl_2006_03_097 crossref_primary_10_2165_00063030_200014060_00002 crossref_primary_10_1016_j_trsl_2013_08_003 crossref_primary_10_2165_00003088_200443060_00002 crossref_primary_10_1345_aph_1E287 crossref_primary_10_1016_j_jpba_2007_11_018 crossref_primary_10_1111_j_1529_8019_2007_00136_x crossref_primary_10_1016_j_jddst_2017_05_017 crossref_primary_10_1177_009127002762491389 crossref_primary_10_1007_s00228_014_1771_1 crossref_primary_10_1016_j_transproceed_2009_06_038 crossref_primary_10_1517_17425255_1_3_487 crossref_primary_10_1097_FTD_0b013e3181cd550f crossref_primary_10_1111_bcp_14590 crossref_primary_10_1016_S1053_2498_01_00305_9 crossref_primary_10_1097_00007691_200110000_00003 crossref_primary_10_1007_s12185_012_1086_x crossref_primary_10_4045_tidsskr_11_0138 crossref_primary_10_1046_j_1468_3083_2000_00019_x crossref_primary_10_1007_s00228_010_0846_x crossref_primary_10_1074_jbc_M111_271288 crossref_primary_10_1097_00007890_199902270_00001 crossref_primary_10_3389_fphar_2018_00908 crossref_primary_10_1016_S0009_9120_99_00101_0 crossref_primary_10_1124_dmd_120_000133 crossref_primary_10_1248_yakushi_125_177 crossref_primary_10_1016_j_jddst_2018_06_005 crossref_primary_10_1111_ctr_14445 crossref_primary_10_1097_FTD_0b013e31817d7064 crossref_primary_10_1177_0961203306071671 crossref_primary_10_1097_FTD_0b013e318166eba0 crossref_primary_10_1046_j_1523_1755_2003_00228_x crossref_primary_10_1158_0008_5472_CAN_04_1553 crossref_primary_10_1186_1479_5876_7_64 crossref_primary_10_5649_jjphcs_37_277 |
ContentType | Journal Article |
Copyright | 1998 INIST-CNRS |
Copyright_xml | – notice: 1998 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.2165/00003088-199834060-00002 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1179-1926 |
EndPage | 455 |
ExternalDocumentID | 10_2165_00003088_199834060_00002 9646007 2441708 |
Genre | Journal Article Review |
GroupedDBID | --- -5G -BR -EM .GJ .XZ 0VX 199 29B 2JY 34G 36B 39C 3V. 4.4 406 53G 5GY 5RE 6I2 6J9 6PF 7X7 88E 8FI 8FJ 8R4 8R5 8UJ 95. AAAUJ AABHQ AADNT AAFGU AAIAL AAIKX AAJKR AAKAS AANZL AAPBV AARHV AATNV AAWTL AAYFA AAYQN AAYTO ABDZT ABFTV ABIPD ABJOX ABKCH ABKMS ABKTR ABOCM ABPLI ABPTK ABTKH ABTMW ABUWG ABWBT ABXPI ACBMV ACBRV ACBYP ACCUX ACGFO ACGFS ACIGE ACMJI ACMLO ACOKC ACREN ACTTH ACVWB ADBBV ADFRT ADFZG ADHHG ADJJI ADMDM ADQRH ADRFC ADURQ ADYOE ADZCM ADZKW AEBTG AEFTE AEJHL AEJOU AEJRE AENEX AEOHA AEPKY AEPYU AESKC AEVLU AEXYK AEYRQ AFALF AFFNX AFKRA AFNRJ AFWTZ AFZKB AGAYW AGDGC AGGBP AGQMX AHIZS AHKMG AHMBA AHSBF AIAKS AILAN AJDOV AJRNO ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF ASKOH ASPBG AVWKF AWSVR AXYYD AZFZN A~4 BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 DCUDU DNIVK DPUIP DU5 EBLON EBS EJD EMOBN ESX F5P F8P FERAY FLLZZ FNLPD FSGXE FYUFA HF~ IAO IEA IHR IMOTQ INH INR IQODW ITC IWAJR J-C JZLTJ LLZTM M1P M4Y NQJWS NU0 NXXTH OAC OPC OVD P2P PQQKQ PROAC PSQYO Q2X ROL RSV RZALA SISQX SNPRN SNX SOHCF SOJ SPKJE SRMVM SSLCW TEORI TSG U5U U9L UAX UG4 UKHRP UNMZH UPIKM UPOSE UTJUX VDBLX VFIZW W48 WAF YQY Z0Y Z7U Z7V Z7W Z81 Z83 Z87 ZGI ZXP ~JE 0R~ AACDK AASML AAYZH ABAKF ABJNI ABWHX ACAOD ACCOQ ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AIZAD ALIPV CGR CUY CVF ECM EIF FIGPU HMCUK LGEZI LOTEE NADUK NPM SJYHP ZMTXR AAYXX CITATION |
ID | FETCH-LOGICAL-c405t-23bc2437ecfc534a378f119d13295069a0e30f48d8dd4e114ad0775b5ac2d80d3 |
ISSN | 0312-5963 |
IngestDate | Thu Sep 12 18:51:37 EDT 2024 Tue Oct 15 23:19:20 EDT 2024 Sun Oct 29 17:07:00 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Pharmacokinetic pharmacodynamic relationship Mycophenolic acid Diseases of the osteoarticular system Hepatic disease Autoimmune disease Inflammatory joint disease Transplantation Review Kidney Food drug interaction Blood plasma Liver failure Drug interaction Kidney disease Human Immunopathology Urinary system disease Prodrug Metabolism Protein Chemotherapy Chronic Biological fixation Treatment Rheumatoid arthritis Renal failure Digestive diseases Immunosuppressive agent Pharmacokinetics |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c405t-23bc2437ecfc534a378f119d13295069a0e30f48d8dd4e114ad0775b5ac2d80d3 |
PMID | 9646007 |
PageCount | 27 |
ParticipantIDs | crossref_primary_10_2165_00003088_199834060_00002 pubmed_primary_9646007 pascalfrancis_primary_2441708 |
PublicationCentury | 1900 |
PublicationDate | 1998-06-01 |
PublicationDateYYYYMMDD | 1998-06-01 |
PublicationDate_xml | – month: 06 year: 1998 text: 1998-06-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Auckland |
PublicationPlace_xml | – name: Auckland – name: Switzerland |
PublicationTitle | Clinical pharmacokinetics |
PublicationTitleAlternate | Clin Pharmacokinet |
PublicationYear | 1998 |
Publisher | Adis international |
Publisher_xml | – name: Adis international |
References | 2308896 - Pharm Res. 1990 Feb;7(2):161-6 7600680 - Clin Chem. 1995 Jul;41(7):1011-7 7878933 - Transplant Proc. 1995 Feb;27(1):1421-4 8623466 - Transplant Proc. 1996 Apr;28(2):925-9 8588243 - Ther Drug Monit. 1995 Dec;17 (6):690-9 4557035 - Cancer Chemother Rep. 1972 Feb;56(1):83-7 8811446 - J Chromatogr B Biomed Appl. 1996 Jun 7;681(2):347-53 1826793 - Scand J Immunol. 1991 Feb;33(2):161-73 8588241 - Ther Drug Monit. 1995 Dec;17 (6):681-4 7878701 - Ther Drug Monit. 1994 Dec;16(6):602-7 1448431 - Pharm Res. 1992 Oct;9(10):1306-13 9165564 - Pharmacotherapy. 1997 May-Jun;17 (3):591-8 8728347 - J Clin Pharmacol. 1996 Apr;36(4):332-44 8728345 - J Clin Pharmacol. 1996 Apr;36(4):315-24 1244564 - Nephron. 1976;16(1):31-41 8634753 - J Chromatogr B Biomed Appl. 1996 Jan 12;675(1):119-29 6705425 - Clin Pharmacokinet. 1984 Jan;9 Suppl 1:32-41 7752752 - Lancet. 1995 May 27;345(8961):1321-5 1346731 - Transplantation. 1992 Feb;53(2):428-32 9713576 - Drug Metabol Drug Interact. 1997;14 (1):33-40 8681386 - Cell. 1996 Jun 14;85(6):921-30 8623181 - Transplantation. 1996 Apr 15;61(7):1029-37 7874783 - Clin Chem. 1995 Feb;41(2):295-9 8799515 - Br J Clin Pharmacol. 1996 Jun;41(6):513-6 7645033 - Transplantation. 1995 Aug 15;60(3):225-32 |
References_xml | |
SSID | ssj0008200 |
Score | 2.2218323 |
SecondaryResourceType | review_article |
Snippet | The pharmacokinetics of the immunosuppressant mycophenolate mofetil have been investigated in healthy volunteers and mainly in recipients of renal allografts.... |
SourceID | crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 429 |
SubjectTerms | Absorption Arthritis, Rheumatoid - metabolism Biological and medical sciences Drug Administration Routes Drug Interactions Graft Rejection - metabolism Humans Immunomodulators Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - pharmacokinetics Kidney Transplantation - physiology Liver Failure - metabolism Medical sciences Mycophenolic Acid - administration & dosage Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - pharmacokinetics Pharmacology. Drug treatments Protein Binding Renal Insufficiency - metabolism |
Title | Clinical pharmacokinetics of mycophenolate mofetil |
URI | https://www.ncbi.nlm.nih.gov/pubmed/9646007 |
Volume | 34 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1RT9swELZQeUGaJhhUK6MoD4gXSJbYjhs_phWsgKh4aCXeqiS2pWrQVmt46H79zrGTtAE0tpeocupGue969519d0bojDPBRdjDruwR4VLwcC5n0nclS5SMUoGJKLJ8R2w4obeP4WOjuiRPvez3m3Ul_4MqjAGuukr2H5CtfhQG4DPgC1dAGK4fwnhQljUubQPqn8AZi77Letd8nemeAXOIXXN58bxQcOdpk4u-O7sK0ScQ6Y9-DOP7Agjv4sqrV0pHN3oTymT-xV69u3QX3xdf73s2F1HUNXZsKz1DzFZFt4pqQXLDKBF9dgK3Rkkaowl_aheYItu0qnaJcvbKRFK7wmG8LTVNepuGHAcstJmPBOygToeJCHCPogrex7XzKjfsGz6tyjTE-og1XQy-i3s8DFtoN77u90eVswYC5JtaLvNaJtlLP_77ew_fYjCflskKkFLmFJRGbFJwlPE--myDCyc2mnKAduT8Czp_MPCuL51xXWy3unTOnYe6b_n6EOFSIZymQjgL5Wypk2PV6QhNrq_Gg6Frj9RwM2DmuYtJmukWlDJTWUhoQnqRCgIuAoJ56DOe-JL4ikYiEoJKiJUToXskpmGSYRH5grRRa76Yy68gJsUDAu4pAhtAdTIV4wy4DQebEKhUBB0UlGKaLk3nlClEnFq001K000q0xRDuoO6WPKuJFsYOahv5Vjc4o_qEheO_TPyG9mpFP0Gt_NeL7AKbzNNTqxF_AJd8bKs |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+pharmacokinetics+of+mycophenolate+mofetil&rft.jtitle=Clinical+pharmacokinetics&rft.au=BULLINGHAM%2C+R.+E.+S&rft.au=NICHOLLS%2C+A.+J&rft.au=KAMM%2C+B.+R&rft.date=1998-06-01&rft.pub=Adis+international&rft.issn=0312-5963&rft.eissn=1179-1926&rft.volume=34&rft.issue=6&rft.spage=429&rft.epage=455&rft_id=info:doi/10.2165%2F00003088-199834060-00002&rft.externalDBID=n%2Fa&rft.externalDocID=2441708 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0312-5963&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0312-5963&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0312-5963&client=summon |